Auto Injector Administration of Ketamine for Critically Injured Airmen
Award amount
$749,988Program and phase
STTR · Phase IIAward year
2022Award details
- Awarding agency
- Department of Defense
- Branch
- Air Force
- Recipient company
- RX BANDZ, INC.
- Proposal award date
- 2022-07-20
- Contract end date
- 2023-10-20
- UEI
- DXRED7S6FVE9
- Solicitation number
- X21.B
- Topic code
- AF21B-TCSO1
Research abstract
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Shelf-life Extension for Emergency Medication
- Continue, Expand, and Refine Research and Development of a Hydromorphone Autoinjector
- Stop The Bleed - Save the Warfighter! : Intramuscular Auto-Injector Delivery of Tranexamic Acid (TXA) on the Battlefield
- Extended Utilization of Lifesaving Medications via Autoinjector
- Life-Saving Mini Auto-Injector to Deliver Epinephrine
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- InSITE (Integrated Surface Information Technology Environment)
- Inergy TACFI
- Automated Real-Time Cybersecurity for Edge Computing & IoT Devices
- High-Temperature High-Performance 3D-Printed Ceramics
- Optimizing Verified Content for High Level Defense Customer in Cloud Native Application Deployments
Research funding history
12 SBIR/STTR records share this UEI (2020–2023). Reported award amounts total $6,990,569. Reported amounts are not federal obligations.
Phases: Phase I, Phase II – Direct to Phase II, Phase II
Agencies: Department of Defense